Neurological disorders and adult coeliac disease

JOHN S. MORRIS, A. B. AJDUKIEWICZ, AND A. E. READ

From the Department of Medicine, Bristol Royal Infirmary

SUMMARY An investigation into the incidence of neurological disorder in 30 patients with adult coeliac disease has shown that three patients had severe depression, two had epileptiform convulsions, and one patient only had signs of involvement of the peripheral nervous system. Motor nerve conduction velocity was low in only one patient. When the nerve conduction velocities of the group on a gluten-free diet were compared with the group who were not on a gluten-free diet, there was no statistically significant difference. Similarly, nerve conduction velocities in patients with a low serum pyridoxal level were not significantly different from those with normal serum pyridoxal levels.

Measurements of the serum level of pyridoxal in 30 patients confirmed that pyridoxine deficiency occurs in adult coeliac disease and that the restriction of gluten from the diet appeared to affect pyridoxal levels favourably.

Since the introduction of peroral jejunal biopsy has made a definitive diagnosis of adult coeliac disease possible (Fone, Cooke, Meynell, Brewer, Harris, and Cox, 1960), several authors have commented on the relationship between the condition and neurological disease. The largest reported series is that of Cooke and Smith (1966), who described 16 cases of adult coeliac disease each with a neurological disorder. Peripheral neuropathy in association with adult coeliac disease was seen in a patient described by Binder, Solitare, and Spiro (1967), whilst Hall (1968) reported a patient with the combination of a proximal myopathy and adult coeliac disease.

The nature of the relationship is unknown. In the series reported by Cooke and Smith (1966), some of the patients appeared to respond to parenteral pyridoxine therapy. These authors commented on the similarity between the neurological disorder of adult coeliac disease and that seen in states of disturbed pyridoxine metabolism, and suggested that a similar disorder of pyridoxine metabolism might be pertinent to the occurrence of neurological abnormality in adult coeliac disease.

The present investigation was designed to estimate the frequency with which neurological abnormalities, both clinical and latent, occur in adult coeliac disease and to relate these to serum levels of pyridoxine.

Patients and Methods

Thirty patients with adult coeliac disease were investigated. Nineteen of the patients were female. Their ages ranged from 21 to 76 years. Fourteen of the patients (10 female) had been on a gluten-free diet for six months to 15 years (mean 4·7 years); 10 patients (five female) had been on a low fat diet with dietary supplements, usually of calcium, vitamin D, and folic acid, for one to eight years (mean 4·6 years), and six patients (three female) were undergoing investigation before the start of treatment. In 28 patients the diagnosis had been confirmed by the presence of subtotal villous atrophy in a peroral biopsy of the jejunal mucosa; in the two remaining patients the
diagnosis had been suggested clinically and substantiated by a response to dietary gluten withdrawal. In the treated patients the response to treatment had been judged to be satisfactory although one female patient had required corticosteroid therapy in addition to gluten withdrawal from the diet. One female patient had diabetes which was difficult to control.

All patients underwent a complete neurological examination. Motor nerve conduction velocity was measured in the lateral popliteal nerve to the extensor digitorum brevis (Thomas, Sears, and Gilliatt, 1959). Normal range is 35.6–63.5 m/second). Action potentials were measured in the lateral popliteal nerve in the manner described by Gilliatt, Goodman, and Willison (1961).

(Popliteal nerve was measured in patients and was followed by the attacks consisuted of generalized convulsions, one of which was followed by a transient hemiparesis. Paraesthesiae were complained of by nine (30%) of the 30 patients. Physical signs were seen in only one patient and consisted of muscle wasting, loss of reflexes, and mild sensory impairment.

**Results**

**Clinical Findings**

Three of the patients had severe depression, requiring psychiatric supervision. Two patients had experienced transient attacks of loss of consciousness of an epileptiform type. In one patient the attacks took the form of nocturnal myoclonus, whilst in the other the attacks consisted of generalized convulsions, one of which was followed by a transient hemiparesis. Paraesthesiae were complained of by nine (30%) of the patients. Physical signs were seen in only one patient and consisted of muscle wasting, loss of reflexes, and mild sensory impairment.

**Nerve Conduction Studies**

Motor nerve conduction velocity in the lateral popliteal nerve was measured in 26 of the 30 patients and was within the normal range in all but one. In one patient previous injury prevented the use of the lateral popliteal nerve but the motor nerve conduction velocity in the medial popliteal nerve to the flexor hallucis brevis was within the normal range. In the three remaining patients, although motor nerve conduction velocity could not be measured, the action potentials measured in the lateral popliteal nerve were normal.

**Serum Pyridoxal Levels**

Fifteen patients had low serum levels of pyridoxal (Figure 1). Only four of the 14 patients on a gluten-free diet had levels outside the normal range compared with seven of the 10 patients on a low fat diet.

**Other Findings**

Anaemia occurred in seven patients, of whom three were in the pretreatment group. Serum levels of vitamin B12 were low in only two patients, each of whom was over 70 years of age. Serum calcium levels were lower in the patients on a gluten-free diet (mean 9.3 mg %) compared with those patients on a low fat diet with additional calcium and vitamin D therapy (mean 9.6 mg %). This difference was not statistically significant.

The relationship of all these findings to the neurological findings is given in Tables I, II, and III.

Serum levels of pyridoxal were within the normal range in all three patients with depression. Of the two patients with epileptiform convulsions, one had a low serum pyridoxal level at the time...
Neurological disorders and adult coeliac disease

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (years)</th>
<th>Sex</th>
<th>Duration of Treatment (years)</th>
<th>Clinical Features</th>
<th>Motor Nerve Conduction Velocity (m/sec)</th>
<th>Action Potentials (μv)</th>
<th>Serum Pyridoxal (ng/ml)</th>
<th>Serum Calcium (mg/100 ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>21</td>
<td>F</td>
<td>15</td>
<td>Parasthesiae</td>
<td>60</td>
<td>—</td>
<td>7·0</td>
<td>9·3</td>
</tr>
<tr>
<td>2</td>
<td>29</td>
<td>F</td>
<td>7</td>
<td>Parasthesiae</td>
<td>38</td>
<td>—</td>
<td>2·8 (↓)</td>
<td>8·4</td>
</tr>
<tr>
<td>3</td>
<td>29</td>
<td>F</td>
<td>9</td>
<td>—</td>
<td>12</td>
<td>—</td>
<td>3·7</td>
<td>10·0</td>
</tr>
<tr>
<td>4</td>
<td>31</td>
<td>F</td>
<td>1</td>
<td>Depression, parasthesiae</td>
<td>55</td>
<td>—</td>
<td>3·1</td>
<td>8·9</td>
</tr>
<tr>
<td>5</td>
<td>30</td>
<td>F</td>
<td>17</td>
<td>Depression</td>
<td>38</td>
<td>10</td>
<td>5·2</td>
<td>9·3</td>
</tr>
<tr>
<td>6</td>
<td>48</td>
<td>F</td>
<td>1</td>
<td>—</td>
<td>40</td>
<td>—</td>
<td>3·4</td>
<td>9·4</td>
</tr>
<tr>
<td>7</td>
<td>48</td>
<td>F</td>
<td>1</td>
<td>—</td>
<td>60</td>
<td>12</td>
<td>1·6 (↓)</td>
<td>9·1</td>
</tr>
<tr>
<td>8</td>
<td>52</td>
<td>M</td>
<td>6</td>
<td>—</td>
<td>38</td>
<td>—</td>
<td>3·4</td>
<td>10·4</td>
</tr>
<tr>
<td>9</td>
<td>54</td>
<td>F</td>
<td>11</td>
<td>Parasthesiae</td>
<td>58</td>
<td>10</td>
<td>4·0</td>
<td>9·6</td>
</tr>
<tr>
<td>10</td>
<td>52</td>
<td>F</td>
<td>9</td>
<td>‘Fits'</td>
<td>43</td>
<td>20</td>
<td>1·7 (↓)</td>
<td>9·1</td>
</tr>
<tr>
<td>11</td>
<td>53</td>
<td>M</td>
<td>7</td>
<td>—</td>
<td>50</td>
<td>—</td>
<td>3·5</td>
<td>10·2</td>
</tr>
<tr>
<td>12</td>
<td>51</td>
<td>M</td>
<td>4</td>
<td>Parasthesiae</td>
<td>52</td>
<td>5</td>
<td>3·5</td>
<td>9·8</td>
</tr>
<tr>
<td>13</td>
<td>52</td>
<td>M</td>
<td>5</td>
<td>—</td>
<td>47†</td>
<td>—</td>
<td>3·5</td>
<td>9·1</td>
</tr>
<tr>
<td>14</td>
<td>64</td>
<td>F</td>
<td>1</td>
<td>—</td>
<td>45</td>
<td>—</td>
<td>1·1 (↓)</td>
<td>8·1</td>
</tr>
</tbody>
</table>

Table I Patients on a gluten-free diet

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (years)</th>
<th>Sex</th>
<th>Duration of Treatment (years)</th>
<th>Clinical Features</th>
<th>Motor Nerve Conduction Velocity (m/sec)</th>
<th>Action Potentials (μv)</th>
<th>Serum Pyridoxal (ng/ml)</th>
<th>Serum Calcium (mg/100 ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15</td>
<td>22</td>
<td>F</td>
<td>12</td>
<td>—</td>
<td>—</td>
<td>12</td>
<td>1·8 (↑)</td>
<td>9·3</td>
</tr>
<tr>
<td>16</td>
<td>26</td>
<td>M</td>
<td>7</td>
<td>—</td>
<td>43</td>
<td>—</td>
<td>1·2 (↑)</td>
<td>9·4</td>
</tr>
<tr>
<td>17</td>
<td>35</td>
<td>M</td>
<td>8</td>
<td>Parasthesiae</td>
<td>53</td>
<td>12</td>
<td>&gt;10</td>
<td>9·5</td>
</tr>
<tr>
<td>18</td>
<td>43</td>
<td>F</td>
<td>7</td>
<td>—</td>
<td>45</td>
<td>12</td>
<td>0·6 (↑)</td>
<td>10·5</td>
</tr>
<tr>
<td>19</td>
<td>53</td>
<td>F</td>
<td>5</td>
<td>—</td>
<td>45</td>
<td>10</td>
<td>1·4 (↑)</td>
<td>10·4</td>
</tr>
<tr>
<td>20</td>
<td>62</td>
<td>M</td>
<td>3</td>
<td>‘Fits'</td>
<td>49</td>
<td>—</td>
<td>36</td>
<td>9·3</td>
</tr>
<tr>
<td>21</td>
<td>62</td>
<td>M</td>
<td>1</td>
<td>—</td>
<td>34</td>
<td>—</td>
<td>4·5</td>
<td>10·1</td>
</tr>
<tr>
<td>22</td>
<td>64</td>
<td>F</td>
<td>3</td>
<td>—</td>
<td>44</td>
<td>—</td>
<td>0·9 (↓)</td>
<td>9·6</td>
</tr>
<tr>
<td>23</td>
<td>76</td>
<td>F</td>
<td>5</td>
<td>—</td>
<td>50</td>
<td>7·5</td>
<td>1·0 (↓)</td>
<td>9·5</td>
</tr>
<tr>
<td>24</td>
<td>76</td>
<td>M</td>
<td>6</td>
<td>—</td>
<td>50</td>
<td>1</td>
<td>0·7 (↓)</td>
<td>8·4</td>
</tr>
</tbody>
</table>

Table II Patients with no dietary gluten restriction

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (years)</th>
<th>Sex</th>
<th>Clinical Features</th>
<th>Motor Nerve Conduction Velocity (m/sec)</th>
<th>Action Potentials (μv)</th>
<th>Serum Pyridoxal (ng/ml)</th>
<th>Serum Calcium (mg/100 ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>25</td>
<td>28</td>
<td>F</td>
<td>Depression</td>
<td>60</td>
<td>—</td>
<td>3·5</td>
<td>—</td>
</tr>
<tr>
<td>26</td>
<td>21</td>
<td>M</td>
<td>Parasthesiae, weakness, wasting, sensory impairment, reflex loss</td>
<td>60</td>
<td>6</td>
<td>3·8</td>
<td>9·1</td>
</tr>
<tr>
<td>27</td>
<td>42</td>
<td>F</td>
<td>Parasthesiae</td>
<td>56</td>
<td>—</td>
<td>1·2 (↑), 1·0 (↓)</td>
<td>9·5</td>
</tr>
<tr>
<td>28</td>
<td>41</td>
<td>M</td>
<td>—</td>
<td>39</td>
<td>—</td>
<td>1·0 (↓)</td>
<td>8·7</td>
</tr>
<tr>
<td>29</td>
<td>48</td>
<td>F</td>
<td>—</td>
<td>54</td>
<td>10</td>
<td>0·9 (↓)</td>
<td>8·7</td>
</tr>
<tr>
<td>30</td>
<td>52</td>
<td>F</td>
<td>Parasthesiae</td>
<td>45</td>
<td>5</td>
<td>3·0 (↓)</td>
<td>8·1</td>
</tr>
</tbody>
</table>

Table III Patients undergoing investigation

1 Measured in the medial popliteal nerve to the flexor hallucis brevis.
2 Levels below the normal range.

of his attacks. He has been treated with phenytoin sodium and pyridoxine and has had no further attacks. In the other patient the serum pyridoxal was not measured at the time of the attacks. Motor nerve conduction velocity was not significantly different in the patients with low serum levels of pyridoxal compared with those with normal levels of serum pyridoxal1 (Fig. 2). Similarly, there was no difference when the motor nerve conduction velocity was compared in the group on a gluten-free diet with those patients who were not on a gluten-free diet1 (Fig. 3).

The mean serum calcium level was lower in the group with parasthesia (9·1 mg %) compared with the group with no parasthesia (mean 9·5 mg %) but this difference was not statistically significant.

1 Using the Wilcoxon-White rank sum test.

Discussion

Neurological complications of adult coeliac disease are rarely reported in the literature. Cooke, Fone, Cox, Meynell, and Gaddie (1963) reviewed 50 patients with adult coeliac disease and described four patients (8%) with a neurological disorder. Subsequently, Cooke and Smith (1966) described 16 patients with a neurological disorder and well documented adult coeliac disease.

DEPRESSION

Three patients in this series had severe depression. Other examples of psychiatric disorder occurring in coeliac disease have appeared in the literature. Cooke, Peeney, and Hawkins (1953),
in their review of 100 patients with idiopathic steatorrhoea, described one patient with depression and a further patient with severe involitional melancholia. Benson, Kowlessar, and Sleisenger (1964) described a patient with a psychoneurotic reaction associated with depression in their review of 32 patients with adult coeliac disease. Daynes (1956) was so impressed with personality changes in children with coeliac disease that he proposed a pre-coeliac syndrome. The symptoms of this syndrome, which included irritability, listlessness, and naughtiness, responded dramatically to gluten withdrawal from the diet. Sheldon (1959) said that in his experience psychological disturbance characterized by depression was a prominent feature of childhood coeliac disease.

Whether there is a true increase in the incidence of depressive disorders in adult coeliac disease is, however, difficult to decide. Watts (1966) estimated that 15% of the home population have depressive disorders and do not consult a doctor, only 0.2% coming under the care of a psychiatrist. A 10% incidence of psychiatric disorder in a group of patients attending hospital is, therefore, not surprising.

Additional evidence against a causal relationship between adult coeliac disease and depression was presented by Goldberg (1968), who found that the prevalence of psychiatric illness was broadly comparable in each of three groups of patients with coeliac syndrome, Crohn's disease, and alactasia. He further suggested that patients with psychiatric disorders overrepresent themselves in an outpatient department by being more likely to attend frequently.

**Periods of Loss of Consciousness**

The general incidence of epileptiform attacks in the population is 0.5% (Report by the Research Committee of the College of General Practitioners, 1960). Therefore, although the figures are small, the finding of two patients with epileptiform attacks in a group of 30 patients may be significant. Cooke and Smith (1966) mention five patients with unexplained attacks of unconsciousness in their group of 16 patients with neurological disorders associated with adult coeliac disease. Daynes (1956) found that 25% of his children with the 'pre-coeliac syndrome' had attacks resembling petit mal.

Why patients with adult coeliac disease should get such attacks is not known. There is evidence that pyridoxine deficiency may precipitate convulsions. Snyderman, Carretero, and Holt (1953) gave pyridoxine-deficient diets to two mentally retarded children as a therapeutic measure. On the 76th day of this treatment one child developed convulsions which promptly responded to pyridoxine. Cousins (1954) reviewed 50 children with convulsions all of whom had been on a liquid formula diet with vitamin supplements which did not include pyridoxine. The convulsions responded promptly to the re-introduction of pyridoxine. The present evidence

---

**Fig. 2** Serum pyridoxal and nerve conduction velocity.

**Fig. 3** Dietary gluten and nerve conduction velocity.
is not sufficient to ascribe a causal relationship to pyridoxine deficiency in the epileptiform attacks of adult coeliac disease.

**Paraesthesiae**

Paraesthesiae are not uncommon symptoms in patients with adult coeliac disease, especially at presentation. Benson *et al* (1964) found that 33% of their patients with adult coeliac disease had paraesthesiae and this corresponds with an incidence of 30% in the present series. Spencer (1957) considered that anaemia was the cause of the paraesthesiae seen in the malabsorption syndrome. This was certainly not the cause in the present series. Green and Wollaeger (1960) attributed the paraesthesiae which they found in 28% of their patients with sprue to hypocalcaemia. In this series the mean level of serum calcium was lower in those patients with paraesthesia compared with those without, but the difference was not statistically significant.

**Peripheral neuropathy**

Reports of involvement of the peripheral nervous system in adult coeliac disease are rare. Farmer and Richards (1964) described a patient with a peripheral neuropathy in whom a biopsy of the jejunal mucosa showed changes typical of 'nontropical sprue'. The largest series of patients with involvement of the peripheral nerves in association with adult coeliac disease is that described by Cooke and Smith (1966). The symptoms in these patients occurred more commonly in the legs than in the arms and consisted of pain, weakness, and unsteadiness of gait. Sensory ataxia occurred eventually in most of the patients. Histological changes were seen in nine patients examined at necropsy and included lesions in the cerebral cortex, basal ganglia, brainstem, spinal cord, and sensory ganglia. Nerve and muscle biopsies performed in 10 of the patients revealed changes on both light and electron microscopy (Cooke, Johnson, and Woolf, 1966). Finally Binder *et al* (1967) described one further patient with peripheral neuropathy and histologically proven adult coeliac disease.

In the present series of patients with adult coeliac disease significant involvement of the peripheral nervous system was not seen. Further, nerve conduction studies failed to detect latent neurological abnormality in the legs—the situation where it is said to occur earliest and to be most severe (Cooke and Smith, 1966). Similar studies in diabetics and patients with impairment of renal function have revealed evidence of peripheral nerve involvement in the absence of clinical signs (Gregerson, 1964; Preswick and Jeremy, 1964).

The cause of the involvement of the peripheral nervous system seen in patients with adult coeliac disease is not known. Cooke and Smith (1966) found no relationship between the neurological abnormalities they described and lowered serum levels of folate or vitamin B12; nor did dietary gluten restriction appear to be important.

Cooke and Smith (1966) found that five of their patients with peripheral nerve involvement made an almost complete recovery when given large amounts of parenteral vitamins, including pyridoxine. Peripheral neuropathy may occur in association with disturbed pyridoxine metabolism, for example, the neuropathy which occurs during treatment with isoniazid and hydralazine (Biehl and Vilter, 1954; Raskin and Fishman, 1965), so that it is theoretically possible that pyridoxine deficiency is a cause of the peripheral neuropathy seen in adult coeliac disease. In the present series, however, there was no significant difference between the motor nerve conduction velocities in those patients with a low serum pyridoxal level compared with those with normal serum pyridoxal levels.

We are grateful to Dr B. Anderson and her colleagues at St Bartholomew's Hospital for help with the measurement of serum levels of pyridoxal many of which were performed in her department, and for allowing us to quote her normal ranges. We are also grateful to Dr G. Wakefield, consultant neurologist, Royal United Hospitals, Bath, who performed the nerve conduction studies. We are indebted to Mrs S. Rolliitt for much technical help.

References


John S. Morris, A. B. Ajdukiewicz, and A. E. Read


